Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2026)

Indivior Pharmaceuticals has reported Non-Current Debt over the past 6 years, most recently at $486.0 million for Q1 2026.

  • For Q1 2026, Non-Current Debt rose 56.27% year-over-year to $486.0 million; the TTM value through Mar 2026 reached $486.0 million, up 56.27%, while the annual FY2025 figure was $290.0 million, 7.94% down from the prior year.
  • Non-Current Debt for Q1 2026 was $486.0 million at Indivior Pharmaceuticals, up from $290.0 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $486.0 million in Q1 2026 and troughed at $237.0 million in Q4 2022.
  • A 5-year average of $311.0 million and a median of $306.0 million in 2025 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: dropped 7.94% in 2025 and later skyrocketed 56.27% in 2026.
  • Year by year, Non-Current Debt stood at $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then surged by 32.91% to $315.0 million in 2024, then dropped by 7.94% to $290.0 million in 2025, then surged by 67.59% to $486.0 million in 2026.
  • Business Quant data shows Non-Current Debt for INDV at $486.0 million in Q1 2026, $290.0 million in Q4 2025, and $304.0 million in Q3 2025.